EN | RU
EN | RU

Help Support

Back

Colchicine may help to treat hospitalized COVID-19 patients

Colchicine may help to treat hospitalized COVID-19 patients Colchicine may help to treat hospitalized COVID-19 patients
Colchicine may help to treat hospitalized COVID-19 patients Colchicine may help to treat hospitalized COVID-19 patients

What's new?

In patients infected with COVID-19, colchicine administration may help to treat the patients.

A recently conducted study depicted that in the treatment of hospitalized patients with COVID-19 colchicine may be beneficial. The open-label, prospective, randomized clinical trial (GRECCO-19) explored the effect of treatment with low-dose colchicine on clinical outcomes, cardiac, and inflammatory biomarkers.

Between April 3 and April 27, 2020, the study recruited a total of 105 patients hospitalized with COVID-19 in 16 tertiary hospitals in Greece. It aimed to explore the potential of colchicine to improve clinical outcomes among patients hospitalized with COVID-19. Participants were randomly assigned to receive either standard of care (n=50; 47.6%) or standard of care plus colchicine (n=55; 52.4%).

Both the groups were identical with the majority of the individuals also being given hydroxychloroquine or chloroquine and azithromycin regimen. Colchicine treatment incorporated a 1.5 mg loading dose and a 0.5 mg dose after 1 hour. This was subsequently followed by maintenance doses of 0.5 mg twice daily for up to 21 days.

The primary endpoints assessed were maximum high-sensitivity cardiac troponin level, time for C-reactive protein to reach more than 3 times the upper reference limit, time to deterioration by 2 points on a 7-grade clinical status scale, ranging from able to resume normal activities to death. The secondary endpoints measured were all-cause mortality, the percent of patients requiring mechanical ventilation, and adverse effects.

The median age of enrolled patients was 64 years old and 58.1% (n=61) of participants were men. No significant differences were witnessed between the control and colchicine groups when analyzing median peak high-sensitivity cardiac troponin levels or median maximum C-reactive protein levels as depicted in the following table:

 

Control group

Colchicine group

Median peak high-sensitivity cardiac troponin levels

0.0112 ng/mL

0.008 ng/mL

Median maximum C-reactive protein levels

4.5  mg/dL

3.1  mg/dL

 

The primary clinical endpoint rate (clinical deterioration) was considerably higher for patients who received standard of care alone compared with those who received colchicine as shown in the following table:

 

Patients receiving standard of care alone

 Patients receiving colchicine

Primary clinical end point rate

14.00%

1.80%

 

For patients in the control group, the average event-free survival time was less than patients in the colchicine group. The occurrence of adverse events demonstrated a similarity between the two groups. However, more patients in the colchicine group experienced diarrhea when compared to the control group as depicted in the following table:

 

Control group

Colchicine group

Average event-free survival time

18.6 days

20.7 days

Percentage of patients experiencing diarrhea

18.00%

45.50%

 

Participants who received colchicine had statistically significantly improved time to clinical deterioration. No substantial differences were witnessed in high-sensitivity cardiac troponin or C-reactive protein levels. However, these findings should be cautiously elucidated.

Source:

MPR

Article:

Clinical Benefit Observed With Colchicine in Hospitalized COVID-19 Patients

Authors:

Cassandra Pardini

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: